<DOC>
	<DOCNO>NCT01568164</DOCNO>
	<brief_summary>The purpose prospective , single-armed , multi-center clinical trial establish safety feasibility use BioVentrix PliCath HF System treatment leave ventricular dysfunction appropriate cohort human suffer heart failure .</brief_summary>
	<brief_title>Safety Efficacy Study BioVentrix PliCath HF System</brief_title>
	<detailed_description>Congestive heart failure `` epidemic '' cardiovascular disease ( Eugene Braunwald , NEJM 1997 ) , yet cure . The American Heart Association report nearly five million Americans afflict . Approximately 1.5 million admission US due heart failure ; number one cost-item Medicare , comprise 6 % total expenditure . BioVentrix develop PliCath heart failure system , use place permanent cardiac implant heart purpose exclude scar , reconfiguring abnormal cardiac geometry cause dysfunction , exclude abnormal portion ventricular wall . Conceptually , final configuration SVR achieve place implant . The procedure call PliCath Epicardial Catheter-based Ventricular Restoration System ( ECVR ) design leave ventricular volume reduction patient heart failure magnitude similar predicate surgical procedure , much less invasively . The PliCath HF System utilizes anchor implant scarred portion heart , deploy , exclude scar similar exclude cinch purse string suture patch , render ventricle small , employed surgical setting , without use cardiopulmonary bypass . The PliCath HF System anchor ( implant ) deploy use fluoroscopic imaging .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion Criteria Age 18 80 ; Left Ventricular Ejection Fraction ( LVEF ) &gt; 15 % ≤ 45 % ; NYHA FC IIIV ; Left Ventricular End Systolic Volume ( LVESVI ) ≥60 cc/m² ≤ 120 cc/ m² Contiguous acontractile ( akinetic and/or dyskinetic ) scar locate anteroseptal , apical ( may extend laterally ) region leave ventricle evidence CMR CT ; Maintained standard medical management least 90 day , stable target ( maximum tolerate ) dosage ; Willing competent complete inform consent ; Viability myocardium region remote area intend scar exclusion evidence CMR CT ; Agree require followup visit Exclusion Criteria Calcified ventricular wall area intend scar exclusion verify echocardiography equivalent ; Thrombus intraventricular mass leave atrium ventricle verify echocardiography equivalent ; Cardiac Resynchronization Therapy ( CRT ) device placement ≤ 60 day prior enrollment ; Significant diastolic dysfunction , define pseudonormal Doppler filling pattern E/A ratio &gt; 2 ; Thin wall , paradoxically move septal scar would preclude successful support anchor pair evidence CMR ; Cardiac valve disease , opinion investigator , require surgery ; Intolerance unwillingness take anticoagulation medication ; Functioning pacemaker lead anteroapical RV , , opinion investigator , would interfere anchor placement ; Pulmonary Arterial Pressure &gt; 60 mm Hg via echo ; Myocardial Infarction within 90 day prior enrollment ; Previous CVA TIA result , opinion investigator , significant residual neurological deficit ; Aorto iliac disease would preclude femfem bypass . Previous right neck surgery , previous pericardiotomy , previous leave chest surgery ; Comorbid disease process life expectancy le one year ; Patients lung , kidney and/or liver transplant ; Chronic renal failure serum creatinine &gt; 2 mg/dL ; Pregnant planning become pregnant study ; Enrolled concurrent study observational .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Epicardial Catheter-based Restoration</keyword>
	<keyword>Surgical/Left Ventricular Reconstruction</keyword>
	<keyword>Ventricular Remodeling</keyword>
	<keyword>Dor</keyword>
</DOC>